to perfusion, the heart was stopped by cutting the cardiac muscle to eliminate flow from the systemic circulation (Smith, 1996) . Subsequently, fluid was infused into the common carotid artery cannula at a constant rate of 10 ml/min (perfusion pressure, 75-100 mm Hg) using a Harvard Model 944 dual channel infusion pump (Harvard Apparatus, South Natick, MA). As fluid infused into the left carotid artery, the left cerebral hemisphere received the majority of the fluid flow. To quantify cerebral perfusion flow (F) [ 3 H]-diazepam (0.15 µCi/ml) uptake for 15 s was determined in a discrete experimental group (Takasato et al., 1984) . As such, data are presented for left brain regions.
The perfusion fluid consisted of HCO 3 -buffered physiological saline, containing 128 mM NaCl, 24 mM NaHCO 3 , 4.2 mM KCl, 2.4 mM NaH 2 PO 4 , 1.5 mM CaCl 2 , 0.9 mM MgSO 4 and 9 mM glucose (pH ~7.35; [Na] = 154.4 mM). All solutions were filtered, oxygenated, warmed to 38° C and adjusted to pH 7.35 before perfusion. The Harvard pump allowed input from two syringes that were connected via a four-way valve allowing conduct of a brief vascular washout specifically stated otherwise, as described previously (Smith et. al, 1987 ) and detailed below.
Compounds which were examined included: lobeline, N-n-hexyl choline, N-n-octyl choline,
iodide (NONI) and N-n-decylnicotinium iodide (NDNI). In the experiments evaluating inhibition of [ 3 H]-choline brain uptake, the perfusion was changed subsequently to tracer-free perfusion fluid for 15 s to wash out [ substrates to the perfusion fluid in separate experiments (choline 500 µM and 5 mM; NONI 250 µM).
At the end of each experiment, rats were decapitated and the brain was removed from the skull. Brain was dissected to obtain cortical tissue samples from the left cerebral hemisphere (25-90 mg) (Takasato et al., 1984) . Perfusate samples (50 µl, in duplicate) were collected for determination of perfusate tracer concentrations. All samples were placed in glass vials, weighed and then digested overnight at 50 °C in 1 ml piperidine (1.0 M). Subsequently, 10 ml scintillation fluid (Scintisafe, Fisher Scientific, Pittsburgh, PA) was added to each vial. and NOPI were prepared as previously described (Crooks et al., 1995; Rui et al., 2002) .
Calculations
Concentrations of tracer in brain and perfusion fluid were expressed as dpm/g brain or dpm/ml perfusion fluid, respectively. Blood-brain barrier transport was determined using the initial uptake method, as previously described (Takasato et al. 1984; Smith, 1996 Smith, , 1989 . In This article has not been copyedited and formatted. The final version may differ from this version. 
where Q* is the quantity of were converted to apparent cerebrovascular permeability-surface area products (PA) using the Crone-Renkin equation (Smith, 1989) :
where F is cerebral perfusion fluid flow. In all instances, PA differed by < 2% from K in , because F exceeded K in by > 40 fold.
An apparent inhibition constant (K i ) for choline and nicotine analogs was determined assuming competitive kinetics (Smith et al., 1987 ) from the equation: (Allen et. al., 1996a) . Evaluation of K i was completed after a one-way ANOVA determined significant differences between [ 3 H]-choline PA (ml/s/g) in the presence of the nicotinium analogs (data not shown). Compounds that demonstrated a significant reduction in choline PA (ml/s/g) were assumed to have a competitive interaction at the BBB choline transporter, and thus a Ki was calculated as described previously. For compounds that had a non-significant reduction in choline PA (ml/s/g), a power analysis was performed to determine if the comparison resulted in a P value less than alpha, and thus, physiologic Ki significance could be achieved if more data points were collected. Power analysis limits for significance were set at: 1) choline PA reduction of 0.23 ml/s/g (corresponding to a Ki value of 1 mM; i.e. maximum level set for assumed physiologic relevance), and 2) a percent power of 70%. The level of assumed physiologic relevance was selected, since the main goal of the present work was to identify high-affinity ligands, which may be delivered to brain via this transport system. Higher concentrations are considered less relevant for such brain-directed delivery because of affinity and capacity of the BBB transport system (Smith, 1993) .
Statistics
Data presented are generated from the frontal cerebral cortex with comparable data seen in parietal and occipital cortical regions, as well as the hippocampal, striatal, thalamic, cerebellum and midbrain regions (data not shown). Inhibition of brain [
RESULTS

Inhibition of [ 3 H]-Choline Brain Uptake
Binding of choline and nicotine analogs to the BBB choline transporter was determined by evaluation of their ability to inhibit [ 3 H]-choline uptake into brain. These studies were conducted to provide insight into the potential ability of these compounds not only to bind to the transporter, but to determine their potential ability to be transported across the BBB from the vasculature compartment into brain. Baseline (Table 1) .
It is important to note from previous studies using the capillary depletion method evaluating 
DISCUSSION
Pharmacological intervention in neurological diseases is often limited by poor access of therapeutic agents into the CNS. Approaches to successful therapy in CNS diseases must consider the BBB as a potential impediment. Numerous methods have been used with limited success to deliver polar drugs to the CNS (Pardridge, 1998; 1997) . Use of antibodies, drug lipidization, prodrug development have been used with some success. Use of small molecules that directly target transport proteins to overcome BBB restrictions eliminates the need for the drug to be biotransformed in brain and linking to antibodies. Lipidization can result in an undesirable pharmacokinetic profile (Grieg, 1989) . We have proposed to use BBB transport proteins such as the choline transporter as brain drug delivery vectors for polar drugs (Metting et al., 1998) ; this approach has been successful with regard to the amino acid transporter and the transport of L-DOPA and gabapentin into brain (Smith, 1993) . In this respect, the present study focused on the BBB choline transporter for drug delivery, as this transporter may offer the advantage of delivering cholinergic and nicotine-like drugs to brain (Metting et al., 1998) . Of significance in this report is that the BBB choline transporter efficiently transports choline, a small charged molecule with minimal passive permeation, to brain. Evaluation of this transporter system may afford a possible brain entry portal for similarly charged therapeutic molecules. To date, this system has not been established as a vector for such CNS delivery.
To utilize a BBB transporter protein as a CNS drug delivery vector, multiple factors must be considered. These factors include: 1) kinetic availability to transport physiologic molecules, regard to the novel nicotine analogs studied herein, and will demonstrate delivery of NONI to brain via the BBB choline transporter.
In vivo choline transport at the BBB has been demonstrated to be carrier-mediated and saturable (Cornford et al., 1978; Allen and Smith, 1999; Allen and Smith, 2001 ). Endogenous choline plasma levels are less than the calculated K m for the transporter, and thus, with respect to availability of the transporter, it is not saturated under physiological conditions. These characteristics coupled with the high transport capacity of the choline transporter and the adequate blood-to-brain transfer rate suggests this carrier has the necessary characteristics to deliver therapeutic molecules to brain (Smith, 1993) .
Structural binding requirements of the choline transporter have been extensively characterized in multiple tissues using binding inhibition studies (for a review, see Lockman and Allen, 2002) . Previous studies reveal that the principal structural moiety in the choline molecule required for recognition by the transporter binding site is the quaternary ammonium group, which is believed to interact with a corresponding anionic group on the transporter binding site. Simon et al. (1975) demonstrated this relationship, and observed that simple quaternary ammonium cations such as tetraethylammonium and tetramethylammonium were inhibitors of choline uptake in striatal synaptosomes. Furthermore, when longer alkyl moieties were substituted for the N-methyl and N-ethyl groups, increased binding affinity to the choline transporter was observed (Dowdall et al., 1976) . The increased affinity of these modified compounds was hypothesized to result from a hydrophobic interaction with the lipid membrane (Lerner, 1989) . The present results with the N-n-alkylnicotinium and N-n-alkylpyridinium analogs are consistent with these reports (Table 1) , and demonstrate that: 1) N-nalkylazaaromatic compounds containing long chain n-alkyl groups, and which are charged at This article has not been copyedited and formatted. The final version may differ from this version. physiologic pH, bind significantly to the choline transporter, 2) the hydroxyl group of the choline molecule is not an absolute requirement for binding to the choline transporter, and 3) when the 3-hydroxy group in the choline molecule is removed, replacement of one of the N-methyl groups with a longer N-n-alkyl group results in compounds with good affinity for the choline transporter, and appears to completely overcome the hydroxy group requirement that has been previously observed (Allen et al., 1996b) . As indicated in Table 1 , the transporter affinity of these compounds are close to that of choline itself suggesting comparable binding. As these compounds are required in much lower concentrations in brain to exert effects, the potential to deliver these agents to brain in sufficient quantities to be therapeutic seems likely. Taken together, these findings suggest the N-n-alkyl chains may be interacting with a proximal lipophilic domain and facilitating binding and/or transport.
The N-n-alkylnicotinium compounds evaluated in this study were previously examined for their ability to inhibit nicotine-evoked dopamine release from superfused rat striatal slices (Crooks et al., 1995; Dwoskin and Crooks, 2001; Wilkins et al., 2002) . Importantly, these nicotine analogs were observed to selectively inhibit the α3β2* neuronal nicotinic acetylcholine receptor, which has been suggested to mediate nicotine-evoked dopamine release from its presynaptic terminals in striatum. Specifically, given the ability of NONI to inhibit the effect of nicotine on dopaminergic systems in vitro (IC 50 ~1.1 µM; Crooks et al., 1995; Wilkins et al., 2002 ) and the calculated apparent K i at the BBB choline transporter (Table 1) , the ability of NONI to access the brain via active transport through the BBB choline carrier was further explored.
The results of the present study show that NONI, the N-n-octyl derivative of nicotine, is transported into brain via the BBB choline transporter. This is a significant finding, since from This article has not been copyedited and formatted. The final version may differ from this version.
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jpet.aspetjournals.org Downloaded from structural and physicochemical considerations, one would predict that the ability of NONI to for inhibition is higher. However, the concentrations of NONI required to inhibit the effect of nicotine on dopaminergic systems is significantly lower in the range of 1.1 µM as noted above.
As such, delivery of sufficient NONI to brain to cause effect can occur with these physiologic conditions. Further, considering brain distribution, and the previous demonstration that NONI inhibits nicotine-evoked dopamine release by selectively interacting with the nicotinic receptor subtype mediating this effect, it is likely that NONI may have significant potential as a CNS therapeutic agent, and if it can be shown that NONI has a good brain distribution profile, it may have significant utility in smoking cessation therapy and stroke prevention. The current observations that the charged, polar N-n-alkylnicotinium analogs studied in this report not only inhibited the effect of nicotine on dopamine systems in the CNS, but also gained access to the brain from the periphery, in spite of potential physicochemical limitations, is a key finding in the development of NONI as a potential smoking cessation agent.
Previously, we have identified derivatives of lobeline and isoarecolone that bind to the BBB basic amine transporter (Metting et al., 1998) . In light of the findings that NONI is transported in to brain via the BBB choline transporter, further studies are warranted on lobeline and isoarecolone derivatives to determine if the BBB choline transporter can act as vectormediated uptake system to also deliver these drugs into the brain.
This report provides for the first time, evidence that the BBB choline transporter can be used as a brain drug delivery vector for nicotine and choline analogs. Furthermore, the results suggest that other structurally related charged quaternary ammonium compounds containing lengthy N-n-alkyl groups may also exhibit increased brain distribution via active choline transport.
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